GB201512139D0 - Methods of treatment - Google Patents

Methods of treatment

Info

Publication number: GB201512139D0
Authority: GB; United Kingdom
Prior art keywords: treatment; methods
Prior art date: 2015-07-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB1512139.5A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Zealand Pharma AS

Original Assignee

Zealand Pharma AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-10

Filing date

2015-07-10

Publication date

2015-08-19

2015-07-10 Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS

2015-07-10 Priority to GBGB1512139.5A priority Critical patent/GB201512139D0/en

2015-08-19 Publication of GB201512139D0 publication Critical patent/GB201512139D0/en

2016-07-07 Priority to PCT/EP2016/066210 priority patent/WO2017009199A1/en

Status Ceased legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

GBGB1512139.5A 2015-07-10 2015-07-10 Methods of treatment Ceased GB201512139D0 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GBGB1512139.5A GB201512139D0 (en)	2015-07-10	2015-07-10	Methods of treatment
PCT/EP2016/066210 WO2017009199A1 (en)	2015-07-10	2016-07-07	Methods of treating damage after a stroke

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1512139.5A GB201512139D0 (en)	2015-07-10	2015-07-10	Methods of treatment

Publications (1)

Publication Number	Publication Date
GB201512139D0 true GB201512139D0 (en)	2015-08-19

Family

ID=54013802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB1512139.5A Ceased GB201512139D0 (en)	2015-07-10	2015-07-10	Methods of treatment

Country Status (2)

Country	Link
GB (1)	GB201512139D0 (en)
WO (1)	WO2017009199A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018202865A1 (en)	2017-05-05	2018-11-08	Zealand Pharma A/S	Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002077017A2 (en) *	2001-02-22	2002-10-03	Zealand Pharma A/S	Medical uses of intercellular communication facilitating compounds
JP2003201238A (en) *	2001-12-03	2003-07-18	Yamanouchi Pharmaceut Co Ltd	Pharmaceutical composition for treating cerebral infarction
EP2260859A1 (en) *	2009-06-12	2010-12-15	Zealand Pharma A/S	Compounds acting as peptide gap junction modulators and their uses
EP2473993A1 (en) *	2009-09-03	2012-07-11	Koninklijke Philips Electronics N.V.	Contralateral array based correction of transcranial ultrasound aberration
WO2012088425A2 (en) *	2010-12-22	2012-06-28	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
WO2013073968A2 (en) *	2011-09-12	2013-05-23	Industrial Research Limited	Agents for modulation of cell signalling

2015
- 2015-07-10 GB GBGB1512139.5A patent/GB201512139D0/en not_active Ceased
2016
- 2016-07-07 WO PCT/EP2016/066210 patent/WO2017009199A1/en not_active Ceased

Also Published As

Publication number	Publication date
WO2017009199A1 (en)	2017-01-19

Publication	Publication Date	Title
ZA202006746B (en)	2023-03-29	Methods of treatment
IL285151B1 (en)	2023-03-01	Methods of treating fgf21-associated disorders
IL259783A (en)	2018-07-31	Methods of treatment of malignancies
GB201701673D0 (en)	2017-03-15	Methods of well treatment
IL253803B (en)	2021-06-30	Treatment of hypoparathyroidism
PL3851537T3 (en)	2024-09-16	Treatment of hyperbilirubinemia
ZA201706059B (en)	2023-08-30	Method of treatment with tradipitant
ZA201706257B (en)	2021-01-27	Treatment of wood
SG11201609652RA (en)	2016-12-29	Treatment of polybacterials infections
PL3964213T3 (en)	2024-07-08	Treatment of conduct disorder
GB201410116D0 (en)	2014-07-23	Method of treatment
IL254825A0 (en)	2017-12-31	Methods of treatment with taselisib
IL253028B (en)	2019-12-31	Method of treatment
ZA201705847B (en)	2020-03-25	Treatment of pain
GB201416832D0 (en)	2014-11-05	Methods of treatment
IL255498A (en)	2018-01-31	Treatment of pruritus
GB201408297D0 (en)	2014-06-25	Treatment of cancer
IL253847A0 (en)	2017-09-28	Methods of treating diseases
SG11202005850VA (en)	2020-07-29	Methods of treatment of hypertrigl yceridemia
GB201602802D0 (en)	2016-03-30	Method of treatment
GB201412010D0 (en)	2014-08-20	Treatment of hypertransaminasemia
GB201512139D0 (en)	2015-08-19	Methods of treatment
GB201417456D0 (en)	2014-11-19	Treatment of cancer
GB201511017D0 (en)	2015-08-05	Method of treatment
GB201421982D0 (en)	2015-01-21	Method of treatment

Legal Events

Date	Code	Title	Description
2017-03-15	AT	Applications terminated before publication under section 16(1)